• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Pliant Therapeutics Inc.

    4/22/26 4:31:32 PM ET
    $PLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PLRX alert in real time by email
    DEFA14A 1 plrx2026defa14a.htm DEFA14A PLRX 2026 DEFA 14A

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 14A INFORMATION

    Proxy Statement Pursuant to Section 14(a) of the
    Securities Exchange Act of 1934
    (Amendment No. )
    Filed by the Registrant ☒
    Filed by a Party other than the Registrant ☐

    Check the appropriate box:
    ☐Preliminary Proxy Statement
    ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ☐Definitive Proxy Statement
    ☒Definitive Additional Materials
    ☐Soliciting Material Pursuant to §240.14a-12
    Pliant Therapeutics, Inc.
    (Name of Registrant as Specified in its Charter) 
    Not Applicable
    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check the appropriate box):
    ☒No fee required.
    ☐Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.
    ☐Fee paid previously with preliminary materials.



     
    Your Vote Counts! Smartphone users Point your camera here and vote without entering a control number For complete information and to vote, visit www.ProxyVote.com Control # V95341-P50455 *Please check the meeting materials for instructions on attending the virtual annual meeting. PLIANT THERAPEUTICS, INC. 331 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO, CA 94080 PLIANT THERAPEUTICS, INC. 2026 Annual Meeting Vote by June 10, 2026 11:59 PM ET You invested in PLIANT THERAPEUTICS, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 11, 2026. Get informed before you vote View the Proxy Statement and our 2025 Annual Report to Stockholders on Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 28, 2026. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. Vote Virtually During the Annual Meeting* June 11, 2026 8:30 a.m. Pacific Time Virtually at: www.virtualshareholdermeeting.com/PLRX2026


     
    Vote at www.ProxyVote.com Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. Voting Items Board Recommends V95342-P50455 THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. 1. To elect three class III directors named in the proxy statement to our Board of Directors: 1a. Bernard Coulie, M.D., Ph.D., M.B.A. For 1b. Gayle Crowell For 1c. Steve Krognes, M.B.A. For 2. To approve, by non-binding advisory vote, the resolution approving Named Executive Officer compensation. For 3. To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. For NOTE: In their discretion, the proxies are authorized to vote upon such other business as may properly come before the meeting.


     
     
    Get the next $PLRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PLRX

    DatePrice TargetRatingAnalyst
    10/10/2025Neutral → Underweight
    Analyst
    3/4/2025Buy → Hold
    Needham
    3/4/2025Neutral
    Cantor Fitzgerald
    3/3/2025Buy → Hold
    Stifel
    3/3/2025Outperform → Market Perform
    Leerink Partners
    2/10/2025Overweight → Neutral
    Analyst
    2/10/2025$43.00 → $4.00Buy → Hold
    Canaccord Genuity
    2/10/2025Outperform → Perform
    Oppenheimer
    More analyst ratings

    $PLRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Kuo Minnie

    4 - PLIANT THERAPEUTICS, INC. (0001746473) (Issuer)

    4/17/26 4:42:50 PM ET
    $PLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Cummings Keith Lamont

    4 - PLIANT THERAPEUTICS, INC. (0001746473) (Issuer)

    4/17/26 4:42:44 PM ET
    $PLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Coulie Bernard

    4 - PLIANT THERAPEUTICS, INC. (0001746473) (Issuer)

    4/17/26 4:42:38 PM ET
    $PLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PLRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

    Highlights FORTIFY, the Phase 1b indication expansion trial of PLN-101095 enrolling patients with ICI-refractory solid tumors SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX) today announced a presentation at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, Illinois from May 29 to June 2, 2026. Poster Presentation Title: Cohort Expansion of a Phase I Study of PLN-101095, a First-in-Class Dual αvβ8 /αvβ1 Integrin Inhibitor, in Combination with Pembrolizumab in Patients with Advanced Solid Tumors Refractory to Immune Checkpoint Inhibitors Presenter:Timothy A. Yap, MBBS, Ph.D., Univer

    5/21/26 5:29:30 PM ET
    $PLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Atisama Therapeutics Advances RB042 into Multiple Ascending Dose cohorts of Phase 1 Trial and Appoints Bernard Coulie as Chair of the Board

    RB042 Phase 1 trial advances into multiple ascending dose study cohorts, demonstrating safety and tolerability to date.Dr. Coulie brings more than 25 years of international biopharma leadership and deep expertise in pulmonary disease to the Atisama Board of Directors.MELBOURNE, Australia, May 15, 2026 /PRNewswire/ -- Atisama Therapeutics (formerly Rage Bio) ("Atisama" or the "Company"), an Australian clinical-stage biotechnology company developing novel splice-switching oligonucleotide (SSO) therapeutics for chronic inflammatory disease, today reported progress in the Phase 1 study of its lead candidate, RB042, and announced the appointment of Dr. Bernard Coulie as Chair of the Board of Dire

    5/15/26 10:25:00 AM ET
    $PLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

    First participant dosed in FORTIFY, a Phase 1b indication expansion trial of PLN-101095Oral presentation at AACR 2026 featured updated data from Phase 1 trial of PLN-101095 showing deepening of confirmed responses in checkpoint inhibitor-refractory solid tumors PLN-101095 spotlighted as novel IO approach as part of AACR's 2026 Highlights Plenary Session SOUTH SAN FRANCISCO, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today provided a corporate update and reported first quarter 2026 financial results. "In the first quarter, our team showcas

    5/11/26 4:05:00 PM ET
    $PLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PLRX
    SEC Filings

    View All

    SEC Form 10-Q filed by Pliant Therapeutics Inc.

    10-Q - PLIANT THERAPEUTICS, INC. (0001746473) (Filer)

    5/11/26 4:10:22 PM ET
    $PLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pliant Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - PLIANT THERAPEUTICS, INC. (0001746473) (Filer)

    5/11/26 4:07:10 PM ET
    $PLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by Pliant Therapeutics Inc.

    DEFA14A - PLIANT THERAPEUTICS, INC. (0001746473) (Filer)

    4/22/26 4:31:32 PM ET
    $PLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PLRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Pliant Therapeutics downgraded by Analyst

    Analyst downgraded Pliant Therapeutics from Neutral to Underweight

    10/10/25 8:29:23 AM ET
    $PLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pliant Therapeutics downgraded by Needham

    Needham downgraded Pliant Therapeutics from Buy to Hold

    3/4/25 8:19:24 AM ET
    $PLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald resumed coverage on Pliant Therapeutics

    Cantor Fitzgerald resumed coverage of Pliant Therapeutics with a rating of Neutral

    3/4/25 7:42:23 AM ET
    $PLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PLRX
    Leadership Updates

    Live Leadership Updates

    View All

    Atisama Therapeutics Advances RB042 into Multiple Ascending Dose cohorts of Phase 1 Trial and Appoints Bernard Coulie as Chair of the Board

    RB042 Phase 1 trial advances into multiple ascending dose study cohorts, demonstrating safety and tolerability to date.Dr. Coulie brings more than 25 years of international biopharma leadership and deep expertise in pulmonary disease to the Atisama Board of Directors.MELBOURNE, Australia, May 15, 2026 /PRNewswire/ -- Atisama Therapeutics (formerly Rage Bio) ("Atisama" or the "Company"), an Australian clinical-stage biotechnology company developing novel splice-switching oligonucleotide (SSO) therapeutics for chronic inflammatory disease, today reported progress in the Phase 1 study of its lead candidate, RB042, and announced the appointment of Dr. Bernard Coulie as Chair of the Board of Dire

    5/15/26 10:25:00 AM ET
    $PLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results

    PLN-101095 Phase 1 data showed deep and durable ongoing responses in checkpoint inhibitor refractory solid tumors PLN-101095 accelerated development plan underway with initiation of Phase 1b indication expansion trial SOUTH SAN FRANCISCO, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today provided a corporate update and reported fourth quarter 2025 financial results. "We ended 2025 with encouraging data from our lead oncology program in ICI-refractory patients, an area of unmet medical need, that informed the initiation of our accelerated

    3/11/26 4:05:00 PM ET
    $PLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2024 Financial Results

    Discontinuation of BEACON-IPF following DSMB and outside expert panel recommendation SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today provided a corporate update and reported fourth quarter 2024 financial results. Fourth Quarter and Recent Highlights Bexotegrast Highlights BEACON-IPF discontinued following recommendation from expanded data safety monitoring board (DSMB). Following a prespecified data review and recommendation by the trial's independent DSMB, as well as a secondary r

    3/3/25 4:05:00 PM ET
    $PLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PLRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Pliant Therapeutics Inc.

    SC 13G - PLIANT THERAPEUTICS, INC. (0001746473) (Subject)

    11/14/24 9:00:58 PM ET
    $PLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Pliant Therapeutics Inc.

    SC 13G/A - PLIANT THERAPEUTICS, INC. (0001746473) (Subject)

    11/14/24 5:05:23 PM ET
    $PLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Pliant Therapeutics Inc.

    SC 13G/A - PLIANT THERAPEUTICS, INC. (0001746473) (Subject)

    11/14/24 4:47:50 PM ET
    $PLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PLRX
    Financials

    Live finance-specific insights

    View All

    Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement

    SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX) today announced that its Board of Directors has unanimously adopted a limited duration stockholder rights agreement (the "Rights Agreement") to protect stockholder interests. The Board resolved to adopt the Rights Agreement in response to recent accumulations of the Company's common stock. The Rights Agreement is intended to reduce the likelihood that any entity, person or group is able to gain control of Pliant through open market accumulation without paying all stockholders an appropriate control premium or providing the Board sufficient opportunity to make informed judgments and take

    3/13/25 7:20:00 AM ET
    $PLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis

    Bexotegrast (PLN-74809) at 320 mg was well tolerated over 12 weeks of treatment with no drug-related severe or serious adverse events; No safety concerns identified across all dose cohorts Bexotegrast at 320 mg reduced liver fibrosis markers ELF and PRO-C3 and showed improvements in hepatocyte function and bile flow by contrast MRI imaging relative to placebo at Week 12 The 320 mg data continue to demonstrate antifibrotic effects of bexotegrast, consistent with previous findings Company to host webcast and conference call tomorrow, Monday, February 5 at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., Feb. 04, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX) today announced

    2/4/24 3:29:07 PM ET
    $PLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis

    Bexotegrast (PLN-74809) was well tolerated over 12 weeks of treatment with few discontinuations and no drug-related severe or serious adverse events Bexotegrast reduced both the Enhanced Liver Fibrosis (ELF) score and collagen synthesis biomarker PRO-C3 levels relative to placebo at all doses with statistical significance at the 160 mg dose Bexotegrast-treated patients showed improved liver biochemistry and imaging parameters relative to placebo at Week 12 Company to host webcast and conference call today, Tuesday, September 26 at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), today announced positive data f

    9/26/23 7:30:00 AM ET
    $PLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care